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 Primary hyperoxaluria type 1 (PH1) is due 
to a hepatic defect in glyoxylate metabo-
lism, namely, a decrease or even loss of 
alanine:glyoxylate aminotransferase activ-
ity ( Figure 1 ). Th e disease manifests as 
severe urolithiasis or progressive nephro-
calcinosis, or even both. It is considered to 
be rare but defi nitively remains underre-
ported, with an estimated prevalence rang-
ing from 1 to 3 per million population in 
Europe and North America, but with 
higher rates in inbred populations. 1 A sub-
stantial proportion of patients (up 
to   >  30 % ) is, however, diagnosed only late, 
with end-stage renal disease (ESRD), or, 
even worse, more or less by chance aft er 
failed isolated kidney transplantation. 
 Th e single-copy  AGXT gene is located 
on chromosome 2p37.3. More than 140 
disease-causing mutations in the  AGXT 
gene have been reported so far. 2 Muta-
tions can be found throughout the 11 
exons of the gene. Whole  AGXT gene 
sequencing has become increasingly 
available and is more diagnostically accu-
rate than liver biopsy. 1 
 PH1 is a very heterogeneous disease, 
with surprising differences in clinical 
follow-up even in siblings with the same 
genotype. Th ere are numerous reports on 
this sometimes exorbitant heterogeneity, 
but — currently — no profound explanation 
is visible. Are there environmental factors 
or even modifi er genes responsible for this 
heterogeneity? Or is PH1 still a mono-
genic disorder? To really answer such 
questions, a broader collection of clinical, 
genetic, and therapeutic data from patients 
with PH is needed. 
 In this regard, Harambat and co-
 workers 3 (this issue) report on a major 
population of patients with PH1, provid-
ing signifi cant information on long-term 
follow-up, genotype – phenotype correla-
tion, and the possible diff erences in dis-
ease expression based on regional or 
ethical considerations. Th is retrospective 
analysis of the clinical history of 155 
patients is extremely helpful in approach-
ing a fundamental answer to the questions 
mentioned above. Given the low preva-
lence of this specifi c disease, this is by far 
the highest number of patients reported. 
 What are the authors ’ fi ndings? 
 (1)  Th e disease oft en begins early in life 
(median age at onset, 4 years). 
 (2)  Diagnosis is oft en delayed (median 
age at diagnosis, 7.7 years). 
 (3)  At time of diagnosis, 43 % of patients 
had already reached ESRD. 
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 A genotype – phenotype correlation in patients with primary 
hyperoxaluria type 1 and specific  AGXT mutations has supposedly been 
found, at least for sensitivity to medication and long-term outcome. 
Nevertheless, other determinants, such as environmental factors or 
modifier genes, must play an essential role in the intra- and interfamilial 
heterogeneity of this disease. Harambat and co-workers report on this 
situation, presenting data on a major population of genotyped patients. 
 Kidney International (2010)  77, 383 – 385.  doi: 10.1038/ki.2009.471 
 Th ese data are in accordance with recent 
literature pointing out that diagnosis 
is all too oft en missed for years, even 
though early diagnosis and initiation of 
treatment are crucial. 4 – 6 
 Also, fi ve clinical forms of PH1 were 
diff erentiated: 
 (1)  Infantile oxalosis with early nephro-
calcinosis and renal failure (26 % ). 
 (2)  Childhood recurrent urolithiasis 
and rapid deterioration of renal 
function (30 % ). 
 (3)  Late-onset form with only occa-
sional stone passages in adulthood 
(21 % ). 
 (4)  Diagnosis only aft er failed isolated 
kidney transplantation (10 % ). 
 (5)  Silent disease only diagnosed at 
family screening (13 % ). 
 Th is implies that more than 50 % of 
pa tients are at risk for early ESRD. What 
a number, and what a disaster that 
 diagnosis was made only when the clini-
cal situation had reached that of a multi-
systemic disease (systemic  oxalosis)! Th e 
cruelty of the clinical situation is empha-
sized even more by the fact that patient 
survival was low (74 % at age 50 years) 
and that more than 50 % of patients were 
in ESRD at 30 years of age. In ESRD, sys-
temic oxalosis with deposition of calci-
um oxalate in all extrarenal tissues leads 
to long-term  consequences, including 
cardiomyopathy, cardiac conduction 
disturbances, vasculopathy, heart block, 
treatment-resistant anemia, oxalate osteo p-
athy resulting in debilitating bone and 
joint pain, retinopathy, and, if treated 
late or untreated, early death. 1,7 
 Th e presented data include an inho-
mogeneous collection of patients: 133 
lived in the European Union, but 22 
resided in North Africa, the Middle 
East, or South America. Also, 52 % of 
patients were of Western European 
descent, but 43 % originally came from 
North Africa or the  Middle East. Th e 
authors mention the importance of 
including as many patients as possible 
to provide adequate information, but we 
also have to keep these numbers in mind 
when interpreting the overall data. 
Different ethnic as well as medical 
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example, a substantial proportion of 
incomplete or uncharacterized patients. 
However, there have already been two 
 trials ( n  =  56) showing an association 
between the G508A mutation and a 
 susceptibility to chaperone treatment 
(pyridoxine) with a greater reduction of 
urinary oxalate excretion to (near) normal 
levels in homozygous patients ( n  =  14), 
but still partial response in heterozygous 
individuals. 12,13 With 12 more G508A-
homozygous patients, Harambat  et al. 3 
nearly double the number of reported 
patients with a signifi cant reduction of 
urinary oxalate excretion and a superior 
follow-up. Although this is a very promis-
ing proof of principle of chaperone treat-
ment, one must keep in mind that 
pyridoxine is only working in a minority 
of patients ( ~ 5 % of the PH1 population), 
as most patients are compound heterozy-
gotes. Other centers (including ours) were 
unable to reconfi rm the pyridoxine eff ect 
to this extent. Th is might be due to rather 
late diagnosis of a signifi cant number of 
homozygous patients (in ESRD) and their 
unclear benefi t from pyridoxine adminis-
tration. In addition, signifi cant intrafamil-
iar differences of B 6 effectiveness in 
G508A homozygotes were observed 8 (our 
unpublished observations). 
 Are the data reported by Harambat and 
colleagues 3 therefore substantial enough 
to fi nally correlate a genotype to a specifi c 
phenotype? Or is the population of 
patients too heterogeneous for a profound 
conclusion? Indeed, the numbers reported 
are high for such a rare disease but remain 
too small for a profound answer. It can 
still be stated only that PH1 contains a 
very heterogeneous clinical spectrum 
reaching from infantile oxalosis with early 
ESRD to (mono)symptomatic stone dis-
ease in the elderly, further complicated by 
an even more disturbing profound intra-
familial variability — despite equal geno-
type. 14,15 Harambat and co-workers 3 
report on substantial diff erences in disease 
expression related to the region of resi-
dency. Th is may or may not be related to 
the genotype of patients. Hence, it would 
have been interesting to know whether the 
phenotype of non-white PH1 patients 
living in France is diff erent from that of 
white residents. Th erefore, a collection of 
a larger cohort of families worldwide and 
 backgrounds may have produced a 
significant bias regarding first symp-
toms, delay until diagnosis, and time to 
ESRD, but also in regard to genotype –
 phenotype correlations. However, a sub-
group  analysis showed interesting, 
although not surprising, results: as 14 of 
the 22 non-European residents already 
presented in ESRD at time of diagnosis 
(64 % ), as renal survival was worse in 
this group (7 % at age 30 years), and as 
the median age of survival without 
ESRD was signifi cantly lower (9 versus 
28 years,  P  <  0.002), the low-income 
region of residence was correlated with 
an increased risk of ESRD. 
 Keeping in mind the devastating con-
sequences of renal failure, but also the 
enormous risks and costs involved with a 
curative treatment (pre-emptive liver or 
combined liver – kidney transplantation), 
a prediction of the natural course of the 
disease for each individual patient would 
represent a major medical breakthrough 
in terms of management — for example, 
the timing of interventions and reduction 
of the risk of untimely procedures. Th is 
would apply even more to patients of the 
low-income regions. 
 However, are we really approaching 
a predictive model? As the clinical hete-
rogeneity does not allow us any specifi c 
prediction, not even in siblings and espe-
cially not in prenatal consultations, we 
have to focus on other parameters pos-
sibly correlated to a clinical course or 
thera peutic intervention. Here, the diag-
nostic genotyping and its correlation to 
the clini cal phenotype could give a basis 
for such a predictive model. Thus far, 
however, there has been limited success 
in establishing genotype – phenotype 
correlations. Nevertheless, genotype –
 phenotype corre lation has already been 
described for some mutations of the 
 AGXT gene. 4,8 – 10 
 In this respect, the contribution of 
 Harambat  et al. 3 helps us take one step 
further, as it off ers additional evidence to 
solve our predictive dilemma. Why? Let 
us focus on patients either homozygous 
(here  n  =  12) or heterozygous ( n  =  24) for 
the most common mutation, c.508G  >  A. 
Previous studies, rather small in numbers 
and restricted to a few mutations, were 
unable to provide sound data on genotype –
 phenotype correlations or yielded con-
flicting results for various reasons, for 
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 Figure 1  |  Glyoxylate metabolism in patients with primary hyperoxaluria type I and II. 
X expresses block by enzymatic defect in case of primary hyperoxaluria type I (alanine:glyoxylate-
aminotransferase (AGT); red) and in case of primary hyperoxaluria type II (glycolate-reductase/
D-glycerate-dehydrogenase (GR), hydroxypyruvate-reductase (HPR); blue). Glycolate-
oxidase (GO), D-amino-oxidase (DAO), lactate-dehydrogenase (LDH), glutamate:glyoxylate-
aminotransferase (GGT), hydroxypyruvate-decarboxylase (HPDC), aldehyde-dehydrogenase 
(ADH), glycolate-dehydrogenase (GDH), D-glycerate dehydrogenase (DGDH). 
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 subsequent careful analysis (for example, 
by region, ethnic background, and medical 
system) would lead to better identifi cation 
of true genotype – phenotype correlations, 
but also genetic and environmental modi-
fi ers responsible for the variability in dis-
ease expression. In this regard, the current 
collaboration between the pan-European 
Hyperoxaluria Consortium (OxalEurope) 
and the Mayo Clinic Hyperoxaluria Center 
(USA) will help by creating a database with 
significant numbers for genotype –
 phenotype studies (an estimated   >  600 PH 
cases worldwide), as well as for the devel-
opment of predictive models. 
 DISCLOSURE 
 The author declared no competing interests. 
 REFERENCES 
 1 .  Hoppe  B ,  Beck  BB ,  Milliner  DS .  The primary 
hyperoxalurias .  Kidney Int  2009 ;  75 :  1264 – 1271 . 
 2 .  Williams  EL ,  Acquaviva  C ,  Amoroso  A  et al.  Primary 
hyperoxaluria type 1: update and additional 
mutation analysis of the AGXT gene .  Hum Mutat 
 2009 ;  30 :  910 – 917 . 
 3 .  Harambat  J ,  Fargue  S ,  Acquaviva  C  et al. 
 Genotype – phenotype correlation in primary 
hyperoxaluria type 1: the p.Gly170Arg AGXT 
mutation is associated with a better outcome . 
 Kidney Int  2010 ;  77 : 443–449 . 
 4 .  Van Woerden  CS ,  Groothoff  JW ,  Wanders  RJ  et al. 
 Primary hyperoxaluria type 1 in The Netherlands: 
prevalence and outcome .  Nephrol Dial Transplant 
 2003 ;  18 :  273 – 279 . 
 5 .  Hoppe  B ,  Langman  C .  A United States survey on 
diagnosis, treatment and outcome of patients 
with primary hyperoxaluria .  Pediatr Nephrol  2003 ; 
 18 :  986 – 991 . 
 6 .  Kopp  N ,  Leumann  E .  Changing pattern of primary 
hyperoxaluria in Switzerland .  Nephrol Dial 
Transplant  1995 ;  10 :  2224 – 2227 . 
 7 .  Herrmann  G ,  Krieg  T ,  Weber  M  et al.  Unusual 
painful sclerotic like plaques on the legs 
of a patient with late diagnosis of primary 
hyperoxaluria type I .  Br J Dermatol  2004 ;  151 : 
 1104 – 1107 . 
 8 .  Hoppe  B ,  Danpure  CJ ,  Rumsby  G  et al.  A vertical 
(pseudodominant) pattern of inheritance 
in the autosomal recessive disease primary 
hyperoxaluria type I. Lack of relationship 
between genotype, enzymic phenotype and 
disease severity .  Am J Kidney Dis  1997 ;  29 : 
 36 – 44 . 
 9 .  Danpure  CJ .  Molecular aetiology of primary 
hyperoxaluria type 1 .  Nephron Exp Nephrol  2004 ; 
 98 :  e39 – e44 . 
 10 .  Rumsby  G ,  Williams  E ,  Coulter-Mackie  M . 
 Evaluation of mutation screening as a first line test 
for the diagnosis of the primary hyperoxalurias . 
 Kidney Int  2004 ;  66 :  959 – 963 . 
 11 .  Pirulli  D ,  Marangella  M ,  Amoroso  A .  Primary 
hyperoxaluria: genotype-phenotype correlation .
  J Nephrol  2003 ;  16 :  297 – 309 . 
 12 .  Monico  CG ,  Rossetti  S ,  Olson  JB  et al.  Pyridoxine 
effect in type I primary hyperoxaluria is associated 
with the most common mutant allele .  Kidney Int 
 2005 ;  67 :  1704 – 1709 . 
 13 .  Van Woerden  CS ,  Jaap  W ,  Groothoff  F  et al. 
 Clinical implications of mutation analysis in 
primary hyperoxaluria type 1 .  Kidney Int  2004 ;  66 : 
 746 – 750 . 
 14 .  Lorenzo  V ,  Alvarez  A ,  Torres  A  et al.  Presentation 
and role of transplantation in adult patients with 
type 1 primary hyperoxaluria and the I244T AGXT 
mutation: single-center experience .  Kidney Int 
 2006 ;  70 :  1115 – 1119 . 
 15 .  Hoppe  B ,  Latta  K ,  von Schnakenburg  C  et al. 
 Primary hyperoxaluria: the German experience . 
 Am J Nephrol  2005 ;  25 :  276 – 281 . 
 commentar y 
see original article on page 450
 Endocrine dysfunction is common in 
patients with chronic kidney disease 
(CKD), especially those near end-stage 
renal disease and those on renal replace-
ment. One of the dysfunctions is the 
growth hormone – insulin-like growth 
factor-1 (GH – IGF-1) axis. 
 Figure 1 is a schematic representation 
of the physiology of the GH – IGF-1 axis, 
showing that the hypothalamus produces 
GH-releasing hormone (GHRH) and 
somatostatin to, respectively, stimulate 
and suppress GH secretion. GH acts on 
many target tissues, but most importantly, 
it stimulates the liver to synthesize IGF-1, 
which accounts for most of the circulating 
IGF-1. GH also stimulates many target tis-
sues to produce IGF-1 that acts locally in 
an autocrine / paracrine fashion. It appears 
that the locally made IGF-1 is as impor-
tant as that produced by the liver, because 
liver IGF-1 knockout mice grew normally. 
IGF-1 receptors are present ubiquitously 
in almost all tissue, including cartilage, 
bone, muscle, liver, kidney, and the nerv-
ous system. In circulation, IGF-1 is bound 
to six binding proteins; 80 % of which is 
IGF-binding protein-3 (IGFBP-3), which 
is the active moiety. IGF-1 bound to other 
binding proteins is physiologically inhib-
itory with regard to its function. Th e GH – 
IGF-1 axis regulates statural growth and 
body composition, the latter through 
enhanced protein synthesis and lipolysis. 
 Th e dysfunction in the GH – IGF-1 axis 
in CKD patients is not due to abnormal 
central hypothalamic – pituitary regulation 
but lies in tissue resistance to both mole-
cules. Th e circulating level of GH is high 
and that of IGF-1 either normal or low; a 
normal IGF-1, in the presence of high GH, 
suggests that the liver is not responding 
adequately to the GH. In the liver and 
many target tissues where GH and IGF-1 
exert their physiological action, there is a 
post-receptor defect in the phosphoryla-
tion of various tyrosine kinases along the 
JAK – STAT transduction pathway. 1,2 
 The most prominent clinical conse-
quence of the GH – IGF-1 axis abnormality 
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 A powerful new agonist: flooding 
the system with growth hormone 
 Victoria S.  Lim 1 
 Niemczyk  et al. treated predialysis chronic kidney disease patients with 
a new growth hormone-releasing hormone agonist, AKL-0707, and 
noted important changes in body composition characterized by an 
increase in fat-free mass, a modest rise in bone mineral content, and a 
reduction in fat mass. These changes were accompanied by a reduction 
in both serum urea nitrogen and normalized protein nitrogen 
appearance rate, while dietary protein intake was unchanged. 
Importantly, there were no serious adverse events. 
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